Frequency of epistaxis and telangiectasia in patients with hereditary hemorrhagic telangiectasia (HHT) in comparison with the general population: Curaçao diagnostic criteria revisited

• Published in: Genetics in medicine Vol. 25; no. 8; p. 100865
• Main Authors: McDonald, Jamie, Kornish, Jenna, Stevenson, David A., Hanson-Kahn, Andrea, Balch, Heather, James, John, Naik, Hetanshi, Whitehead, Kevin J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-08-2023
• Subjects: Curaçao criteria; Diagnostic criteria; Epistaxis; Hereditary hemorrhagic telangiectasia; Telangiectasia; Epistaxis; Curaçao criteria; Hereditary hemorrhagic telangiectasia; Diagnostic criteria; Telangiectasia
• ISSN: 1098-3600; 1530-0366
• DOI: 10.1016/j.gim.2023.100865

The Curaçao criteria are well-established diagnostic criteria for hereditary hemorrhagic telangiectasia (HHT), but they lack details regarding a predictive presentation of epistaxis and telangiectasias. This study collects and compares data in HHT and population cohorts to inform the application of these criteria.
In-person interviews regarding epistaxis and targeted examination for telangiectases in a general population cohort (n = 204) and an HHT cohort (n = 432) were conducted.
Frequency of epistaxis, rather than intensity or duration, was the best discriminator of HHT. A cutoff of ≥4 nosebleeds per year alone yielded a diagnostic sensitivity of 97%, and specificity of 84%. The mean number of telangiectases at the sites investigated was 0.4 in the general population cohort and 26.5 in the HHT cohort. The most distinctive sites for telangiectases in HHT were lips and palmar fingers, whereas telangiectases of the face and dorsum of the hand were comparable in both cohorts.
We propose that the Curaçao criteria be modified to include the following cutoffs: (1) epistaxis frequency of ≥4 nosebleeds per year and (2) telangiectasia count of at least 2 in characteristic locations (palmar aspect of fingers, lips, and oral cavity), and that cutaneous telangiectases at other sites not be considered relevant for diagnostic purposes.